{
    "id": 5432,
    "name": "bladder papillary transitional cell neoplasm",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5432",
    "evidence": [
        {
            "id": 12617,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that lasted more than 6 months in a patient with bladder papillary urothelial carcinoma harboring FGFR3 S249C, and amplification of FGFR3, FGF19, and CCND1 (PMID: 25766722).",
            "molecularProfile": {
                "id": 28792,
                "profileName": "CCND1 amp FGF19 amp FGFR3 S249C FGFR3 amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 5432,
                "name": "bladder papillary transitional cell neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10498,
                    "pubMedId": 25766722,
                    "title": "Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25766722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}